These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Distribution of laminins in the basement membranes of the upper gastrointestinal tract and Barrett's oesophagus. Dave U; Thursz MR; Ebrahim HY; Burke MM; Townsend ER; Walker MM J Pathol; 2004 Mar; 202(3):299-304. PubMed ID: 14991894 [TBL] [Abstract][Full Text] [Related]
4. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672 [TBL] [Abstract][Full Text] [Related]
5. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118 [TBL] [Abstract][Full Text] [Related]
6. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299 [TBL] [Abstract][Full Text] [Related]
7. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Dorer R; Odze RD Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330 [TBL] [Abstract][Full Text] [Related]
8. Molecular evaluation of ablative therapy of Barrett's oesophagus. Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364 [TBL] [Abstract][Full Text] [Related]
9. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus. Asthana N; Mandich D; Ligato S Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240 [TBL] [Abstract][Full Text] [Related]
10. Alteration of glutathione S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. Cobbe SC; Scobie GC; Pohler E; Hayes JD; Kernohan NM; Dillon JF Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):41-7. PubMed ID: 12544693 [TBL] [Abstract][Full Text] [Related]
11. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Jankowski JA; Anderson M Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468 [TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717 [TBL] [Abstract][Full Text] [Related]
13. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study. Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320 [TBL] [Abstract][Full Text] [Related]
14. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680 [TBL] [Abstract][Full Text] [Related]
15. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma. Abraham SC; Wang H; Wang KK; Wu TT Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141 [TBL] [Abstract][Full Text] [Related]
16. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675 [TBL] [Abstract][Full Text] [Related]
17. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Fléjou JF Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008 [TBL] [Abstract][Full Text] [Related]
18. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565 [TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754 [TBL] [Abstract][Full Text] [Related]
20. The pathology of epithelial pre-malignancy of the gastrointestinal tract. Guindi M; Riddell RH Best Pract Res Clin Gastroenterol; 2001 Apr; 15(2):191-210. PubMed ID: 11355911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]